56157-93-8Relevant articles and documents
MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO
-
Page/Page column 117, (2019/06/23)
The present invention relates to compounds of Formula (la) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure and related disorders thereto
Improved 3-hydroxythiophenol synthesis
Biggs, Tim,Volek, Tom,Jesionowski, Gary,Romell, Vaughn
, p. 877 - 881 (2013/02/23)
Hydroxythiophenols have provided access to a number of unique heterocycles. Historically, access to 3-hydroxythiophenol has been challenging because of inefficiencies and prohibitive cost. A straightforward and efficient route to 3-hydroxythiphenol has been devised.
Protease inhibitors that overcome drug resistance
-
Page/Page column 8, (2010/02/14)
HIV protease inhibitors are among the most powerful drugs in suppressing HIV in human patients. However, HIV developed resistance to all protease inhibitor drugs so far marketed or used in clinical trials. HIV generates resistance by mutating its protease. The strains of HIV containing mutant proteases less vulnerable to inhibitor drug are able to replicate better and maintain the infection. No effective principle exists for the design of resistance-proof HIV protease inhibitors (HIVPr). A new inhibitor has been developed based on a new concept for designing resistance invulnerable HIVPr inhibitors. In vitro data have shown that this inhibitor is effective against many known HIVPr mutants resistant to other HIVPr inhibitor drugs. The new concept is, therefore, generally applicable for the design of other resistance invulnerable HIVPr inhibitor drugs.